Camurus’ Interim Report Third Quarter 2023
“Strong financial performance and launch of Brixadi™ in the US” Third quarter summary 2023 July - September · Total revenues amounted to SEK 384 (241) million, an increase of 59% (49% at CER[1]), whereof product sales were SEK 346 (241) million, an increase of 44% (38% at CER[1]) · Compared to previous quarter, product sales increased 13% (9% at CER[1]) · Operating result was SEK 104 (41) million, an increase of SEK 63 million (154%) · Cash position at the end of the quarter was SEK 1,154 (520) million, an increase of SEK 634 million (122%) · Number of patients